Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer. - Porter R; Bockorny B; Corr BR; Mahadevan D; Wilky BA; El-Khoueiry AB; Bullock AJ; Hafez N; Moser J; Martynova A; Stebbing J; Joshi B; et al. (Journal for immunotherapy of cancer, 2025)